The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. About Pneumococcal Disease.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

The Pharma Data

MARCH 8, 2021

, preliminary evidence suggests that canakinumab inhibits pro-tumor inflammation (PTI) to 1) enhance anti-tumor immune response; 2) reduce tumor cell proliferation, survival and invasiveness; and 3) impair angiogenesis 8. Canakinumab is a first-in-class interleukin-1beta (IL-1?) Disclaimer. Source link:[link].

Trials 52

Trials Immune Response Clinical Trials Clinical Trials 52

Drug Discovery World

OCTOBER 21, 2022

New research has identified immune targets for chemotherapy-resistant breast cancers. The research sheds light on the function of immune cells in these patients and will help future studies to enhance the anti-cancer immune response in breast cancer.

In-Vivo 52

In-Vivo Research Drugs Engineer 52

The Pharma Data

NOVEMBER 18, 2020

Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing.

Production 40

Production Containment Immune Response Regulation 40

The Pharma Data

OCTOBER 19, 2020

The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Disclaimer.

Containment 52

Containment Clinical Trials Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Moderna”) contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Sanofi, Empowering Life.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

JANUARY 24, 2021

In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines.

Development 52

Development Vaccination Vaccine Production 52

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. This press release contains “forward-looking statements” of. With more than 100,000 people in 100 countries, Sanofi. Empowering Life. Moderna, Inc.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

DECEMBER 18, 2020

The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein. Director of the FDA’s Center for Biologics Evaluation and Research.

Vaccination 52

Vaccination Vaccine Production Manufacturing 52

Drug Discovery World

AUGUST 31, 2023

Until now, scientists believed it didn’t contain ‘true’ epithelial stem cells, but only progenitors arising in foetal development. They can develop into epithelial as well as muscle and neuroendocrine cells, highlighting the importance of the thymus in hormonal regulation.

Research 59

Research Immune Response Scientist Hormones 59

The Pharma Data

OCTOBER 21, 2020

Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. About Replimune Replimune Group, Inc.,

Gene Therapy 40

Gene Therapy Immune Response Sales Gene 40

Delveinsight

JANUARY 22, 2021

Albeit, in the past two decades, a lot has been learnt and understood about the etiology of the pathogenesis of Drug-Induced Thrombocytopenia, the knowledge of the molecular nature of the drugs, immune-response to the drugs and the production of antibodies in the body is far from complete.

Marketing 65

Marketing Drugs Antibody Compliance 65

The Pharma Data

SEPTEMBER 9, 2020

During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response. The information contained in this release is as of September 7, 2020. Pfizer Disclosure Notice. For more information, please visit www.BioNTech.de. BioNTech Forward-looking Statements.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

MAY 7, 2021

population in just a few months, the BLA submission is an important cornerstone of achieving long-term herd immunity and containing COVID-19 in the future,” said Ugur Sahin, M.D., regulators to seek approval of our COVID-19 vaccine based on our pivotal Phase 3 trial and follow-up data.”. CEO and Co-founder of BioNTech. “We

Licensing 52

Licensing Licensing Vaccination Vaccine 52

The Pharma Data

NOVEMBER 10, 2020

Oral administration of anti-CD3 monoclonal antibody is a novel approach to induce an anti-inflammatory immune response to suppress inflammation by inducing T regulatory (Tregs) cells in animal studies 3 ,4. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

The Pharma Data

JANUARY 4, 2021

Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. This press release contains forward-looking statements that involve substantial risks and uncertainties. relevant government policies and regulations relating to our industry.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

Drug Discovery World

AUGUST 2, 2023

Palmitoyl transferases are a zinc finger Asp-His-His-Cystype (ZDHHC) family containing 23 distinct mammalian genes (excluding ZDHHC10) that catalyse this reaction 1. The intracellular storage of PD-L1 and its active redistribution to the cell membrane was shown to play an important role in response to checkpoint inhibitors.

Protein 52

Protein Immune Response In-Vitro Regulation 52

Drug Discovery World

AUGUST 17, 2023

5, though the latter does contain one particular mutation that is known to evade immunity. In addition, our preliminary clinical testing has demonstrated that mRNA-1273.815 is effective in generating an immune response against the current XBB variants of concern.” Focus on Omicron subvariant XBB.1.5 subvariant. .

Vaccination 52

Vaccination Vaccine Immune Response Manufacturing 52

Drug Discovery World

MAY 11, 2023

First, products containing undesired proteases can impair drug stability, either by degrading the drug itself or by degrading stabilising excipients of the drug formulation, which ultimately diminishes the drug’s durability. In the case of therapeutics, the aim is usually to avoid patients’ immune responses.

Production 52

Production Gene Protein Vaccination 52

The Pharma Data

OCTOBER 9, 2021

years of exposure 3 Design of a new open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in MS-patients treated with Kesimpta 4 , and new findings from open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in secondary progressive MS (SPMS) patients treated with Mayzent will be presented 5.

Immune Response 52

Immune Response Vaccination Vaccine Medicine 52

The Pharma Data

OCTOBER 18, 2020

” EB05 is an experimental monoclonal antibody that Edesa believes could regulate the overactive immune response associated with Acute Respiratory Distress Syndrome (ARDS) – the leading cause of death in COVID-19 patients. The company is based in Markham, Ontario, Canada, with a U.S. Sign up for news alerts.

Immune Response 40

Immune Response Antibody Regulation Development 40

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

AUGUST 17, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Immune Response 52

Immune Response Trials Medicine FDA Approval 52

The Pharma Data

NOVEMBER 14, 2020

The interim analysis showed that a single dose of the COVID-19 vaccine candidate induced a robust immune response and was generally well-tolerated. PHASE 3 ENSEMBLE 2 STUDY. For more information on Johnson & Johnson’s multi-pronged approach to helping combat the pandemic, visit: www.jnj.com/coronavirus.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

AUGUST 3, 2021

announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. Loxo Oncology at Lilly and Kumquat Biosciences Inc.

Antibody 52

Antibody Sales Production Development 52

Drug Discovery World

DECEMBER 15, 2022

While viral vectors can be highly active, they can lead to only transient expression (rAAV, AdV), can lead to adverse immune responses (AdV) or can integrate randomly into the genome (LV). In all cases, viral delivery vectors have limited payload capacity which can limit various use cases.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

The Pharma Data

DECEMBER 21, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials 40

Trials Production Sales Manufacturing 40

Pharma Marketing Network

JANUARY 20, 2021

It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

The Pharma Data

SEPTEMBER 3, 2020

The data, published today in Nature Medicine , demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

The Pharma Data

MAY 13, 2021

The early access clinical program plans to administer the vaccine to up to 200,000 individuals beginning with health workers, other frontline workers and others at increased risk of exposure to the Ebola virus (adults and adolescents 14 years and above on a case-by-case basis or depending on national regulations). Follow us at @JanssenGlobal.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

The Pharma Data

JANUARY 29, 2021

The Janssen AdVac® viral vector technology can induce potent and long-lasting humoral and cellular immune responses, enabling the pursuit of vaccines for disease targets that are currently unpreventable or untreatable. Janssen’s COVID-19 vaccine program has been designed to be thorough and driven by science.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. It was recently reported that the addition of an adjuvant to their vaccine led to enhanced immune responses that exceeded responses in convalescent serum from symptomatic COVID-19 patients. That’s if Russia doesn’t get its hands on it first.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92